Cargando…

Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab

Detalles Bibliográficos
Autores principales: Buttgereit, Thomas, Grekowitz, Eva Maria, Metz, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350330/
https://www.ncbi.nlm.nih.gov/pubmed/34401426
http://dx.doi.org/10.1016/j.jdcr.2021.06.028
_version_ 1783735737005375488
author Buttgereit, Thomas
Grekowitz, Eva Maria
Metz, Martin
author_facet Buttgereit, Thomas
Grekowitz, Eva Maria
Metz, Martin
author_sort Buttgereit, Thomas
collection PubMed
description
format Online
Article
Text
id pubmed-8350330
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83503302021-08-15 Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab Buttgereit, Thomas Grekowitz, Eva Maria Metz, Martin JAAD Case Rep Case Report Elsevier 2021-07-09 /pmc/articles/PMC8350330/ /pubmed/34401426 http://dx.doi.org/10.1016/j.jdcr.2021.06.028 Text en © 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Buttgereit, Thomas
Grekowitz, Eva Maria
Metz, Martin
Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
title Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
title_full Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
title_fullStr Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
title_full_unstemmed Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
title_short Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
title_sort baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350330/
https://www.ncbi.nlm.nih.gov/pubmed/34401426
http://dx.doi.org/10.1016/j.jdcr.2021.06.028
work_keys_str_mv AT buttgereitthomas baricitinibrapidlyandsustainablyrelievesapatientfromchronicpruritusofunknownoriginrefractorytodupilumab
AT grekowitzevamaria baricitinibrapidlyandsustainablyrelievesapatientfromchronicpruritusofunknownoriginrefractorytodupilumab
AT metzmartin baricitinibrapidlyandsustainablyrelievesapatientfromchronicpruritusofunknownoriginrefractorytodupilumab